AVIR Atea Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1593899 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-5.7%
TTM EPS YoY-10.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-63.2%
ROA-57.2%
ROIC (approx.)-86.0%
Asset turnover—
Leverage & solvency
Liabilities / assets12.5%
Debt / equity0.00x
Current ratio8.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $27.09M | $28.15M | $41.13M | $47.82M | $38.35M | $32.27M | $29.58M | $25.67M |
| SG&A expense | $6.92M | $6.95M | $6.87M | $7.12M | $7.22M | $9.07M | $9.46M | $13.36M |
| Operating income | -$34.01M | -$35.10M | -$48.01M | -$54.93M | -$45.57M | -$41.34M | -$39.04M | -$39.03M |
| Pretax income | -$32.12M | -$32.91M | -$45.39M | -$51.63M | -$41.85M | -$36.95M | -$34.07M | -$33.32M |
| Income tax | $38,000 | $24,000 | $50,000 | -$6.77M | $196,000 | $207,000 | $203,000 | $225,000 |
| Net income | -$32.16M | -$32.93M | -$45.44M | -$44.87M | -$42.05M | -$37.16M | -$34.27M | -$33.54M |
| EBITDA | -$33.91M | -$34.99M | -$47.90M | -$54.83M | -$45.46M | -$41.24M | -$38.94M | -$38.92M |
| EPS (basic) | -0.40 | -0.41 | -0.57 | — | -0.53 | -0.44 | -0.40 | — |
| EPS (diluted) | -0.40 | -0.41 | -0.57 | — | -0.53 | -0.44 | -0.40 | — |
| Weighted avg. shares (diluted) | 80.22M | 80.05M | 79.20M | — | 79.05M | 83.75M | 85.16M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $97.92M | $76.55M | $79.32M | $95.71M | $77.34M | $87.72M | $119.39M | $64.70M |
| Short-term investments | $93.28M | $142.92M | $176.69M | $206.12M | $251.97M | $291.99M | $306.04M | $390.02M |
| Current assets | $200.27M | $228.66M | $263.20M | $310.99M | $336.14M | $385.60M | $433.71M | $462.36M |
| PP&E, net | $145,000 | $249,000 | $353,000 | $457,000 | $561,000 | $665,000 | $769,000 | $873,000 |
| Total assets | $200.71M | $232.28M | $267.08M | $315.22M | $342.96M | $391.61M | $439.96M | $464.67M |
| Current liabilities | $25.02M | $28.12M | $33.37M | $39.78M | $20.18M | $20.12M | $21.75M | $18.60M |
| Total liabilities | $25.02M | $28.12M | $33.37M | $39.78M | $27.18M | $27.19M | $28.88M | $25.80M |
| Shareholders' equity | $175.68M | $204.16M | $233.71M | $275.43M | $315.78M | $364.42M | $411.08M | $438.87M |
| Shares outstanding | 80.30M | 80.20M | 80.03M | 78.13M | 78.13M | 81.14M | 85.58M | 84.46M |
| Cash flow statement | ||||||||
| Operating cash flow | -$28.87M | -$37.08M | -$46.39M | -$28.22M | -$40.38M | -$32.87M | -$30.56M | -$30.40M |
| Investing cash flow | $50.05M | $34.31M | $29.74M | $46.59M | $41.30M | $15.29M | $85.61M | -$3.37M |
| Financing cash flow | $195,000 | $0 | $257,000 | $0 | -$11.30M | -$14.09M | -$347,000 | $0 |
| Depreciation & amortization | $104,000 | $104,000 | $104,000 | $104,000 | $104,000 | $104,000 | $104,000 | $104,000 |
| Stock-based compensation | $3.47M | $3.38M | $3.73M | $4.58M | $4.52M | $4.67M | $6.95M | $14.30M |
| Share buybacks | — | — | — | $0 | $11.43M | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.